PU.1 and BCL11B sequentially cooperate with RUNX1 to anchor mSWI/SNF to poise the T cell effector landscape
Gamble N*, Bradu A*, Caldwell JA*, McKeever J, Bolonduro O, Ermis E, Kaiser C, Kim Y, Parks B, Klemm S, Greenleaf WJ, Crabtree GR and Koh AS. Nat Immunol, In press, 2024. *Equal contributors.
The CD8+ T cell tolerance checkpoint triggers a transcriptionally and epigenetically distinct differentiation state defined by protein translation defects
Van Der Byl W, Nüssing S, Peters TJ, Ahn A, Li H, Ledergor G, David E, Koh AS, Wagle MV, Deguit CDT, de Menezes MN, Travers A, Sampurno S, Ramsbottom KM, Li R, Kallies A, Beavis PA, Jungmann R, Bastings MMC, Belz GT, Goel S, Trapani JA, Crabtree GR, Chang HY, Amit I, Goodnow CC, Luciani F and Parish IA. Immunity, Accepted, 2024.
Venetoclax induces Treg to TH17 plasticity to enhance anti-PD-1 checkpoint blockade and reveals a non-apoptotic role of BCL-2 in Treg homeostasis
Liao R, Hsu JY, Aboelella NS, McKeever JA, Thomas-Toth AT, Koh AS and LaBelle JL. Cancer Immunology Research, Accepted, 2024.
AIRE in context: Leveraging chromatin plasticity to trigger ectopic gene expression
Kaiser C*, Bradu A*, Gamble N*, Caldwell JA and Koh AS. Immunol Rev, 305(1):59-76, 2022. *Equal contributors.
Rapid chromatin repression by Aire provides precise control of immune tolerance.
Koh AS*, Miller, EL, Buenrostro, JD, Moskowitz DM, Wang J, Greenleaf, WJ, Chang HY and Crabtree GR*. Nat Immunol, 19(2):162-172, 2018. *Corresponding authors.
Global relevance of Aire binding to hypomethylated lysine-4 of histone-3.
Koh AS, Kingston RE, Benoist C and Mathis D. Proc Natl Acad Sci USA, 107(29), 13016-21, 2010.
Aire employs a histone-binding module to mediate immunological tolerance, linking chromatin regulation with organ-specific autoimmunity.
Koh AS, Kuo AJ, Park SY, Cheung P, Abramson J, Bua D, Carney D, Shoelson SE, Gozani O, Kingston RE, Benoist C and Mathis D. Proc Natl Acad Sci USA, 105(41), 15878-83, 2008. Highlighted in Cell, 135(5), p769, 2008, F1000Prime recommended, 2009.
T cell responses to HLA-A*0201-restricted peptides derived from human alpha fetoprotein.
Butterfield LH, Meng WS, Koh A, Vollmer CM, Ribas A, Dissette VB, Faull K, Glaspy JA, McBride WH and Economou JS. J. Immunology, 166(8), 5300-5308, 2001.
Immune deviation and Fas-mediated deletion limit antitumor activity after multiple dendritic cell vaccinations in mice.
Ribas A, Butterfield LH, Hu B, Dissette VB, Meng WS, Koh A, Andrews KJ, Lee M, Amar SN, Glaspy JA, McBride WH and Economou JS. Cancer Research, 60(8), 2218-2224, 2000.
Generation of T-cell immunity to a murine melanoma using MART-1-engineered dendritic cells.
Ribas A, Butterfield LH, Hu B, Dissette VB, Chen AY, Koh A, Glaspy JG, McBride WH and Economou JS. J. Immunotherapy, 23(1), 59-66, 2000.
Characterization of antitumor immunization to a defined melanoma antigen using genetically engineered murine dendritic cells.
Ribas A, Butterfield LH, McBride WH, Dissette VB, Koh A, Vollmer CM, Hu B, Chen A, Eilber FC, Andrews KJ, Glaspy JA and Economou JS. Cancer Gene Therapy, 6(6), 523-536, 1999.
Generation of human T-cell responses to an HLA-A2.1-restricted peptide epitope derived from alpha-fetoprotein.
Butterfield LH, Koh A, Meng WS, Vollmer CM, Ribas A, Dissette VB, Lee E, Glaspy JA, McBride WH and Economou JS. Cancer Research, 59, 3134-42, 1999.
Alpha-fetoprotein specific genetic immunotherapy for hepatocellular carcinoma.
Vollmer, CM, Eilber FC, Butterfield LH, Ribas A, Dissette VB, Koh A, Montejo L, Andrews KJ, McBride WH, Glaspy JA and Economou JS. Cancer Research, 59, 3064-67, 1999.